Kodiak Sciences Inc.
KOD
शेयरों में रैंक
#3093
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
शेयर मूल्य
$93.69
अंतिम समन्वयन: 2026-10-20
मार्केट कैप
$5.89B
बदलाव (1 दिन)
2.56%
बदलाव (1 वर्ष)
393.11%
देश
US
व्यापार Kodiak Sciences Inc. (KOD)
श्रेणी
Healthcare
Kodiak Sciences Inc. (KOD) के लिए कमाई
Jun 2026 में कमाई TTM: $-241.99M
Kodiak Sciences Inc. की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान कमाई $-241.99M है। 2023 में कंपनी ने $-260.49M की कमाई की, जो 2022 की कमाई $-333.82M के की वृद्धि है। इस पृष्ठ पर दिखाई गई कमाई ब्याज और कर से पहले की कमाई है, जिसे EBIT कहा जाता है।
Kodiak Sciences Inc. के लिए कमाई का इतिहास 2016 से 2026 तक
प्रत्येक वर्ष के अंत में कमाई
| वर्ष | कमाई | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-241.99M | 37.34% |
| 2024 | $-176.21M | -32.36% |
| 2023 | $-260.49M | -21.97% |
| 2022 | $-333.82M | 25.03% |
| 2021 | $-266.99M | 100.60% |
| 2020 | $-133.10M | 181.00% |
| 2019 | $-47.37M | 14.29% |
| 2018 | $-41.44M | 48.35% |
| 2017 | $-27.94M | 63.06% |
| 2016 | $-17.13M | 0.00% |
समान कंपनियों या प्रतियोगियों की कमाई
| कंपनी | कमाई | कमाई में अंतर | देश |
|---|---|---|---|
| $5.27B | -2,279.76% |
US
|
|
| $-3.09B | 1,175.65% |
US
|
|
| $-4.02B | 1,559.63% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -906.07% |
NL
|
